viewCynata Therapeutics Ltd

Cynata Therapeutics achieves progress in stem cell technology

The global regenerative medicine market was worth US$18.9 billion in 2016.

The patent is expected to be granted by October 2017

Cynata Therapeutics (ASX:CYP) has received the Notice of Allowance from the U.S. patent office for a patent application tied to its proprietary Cymerus™ stem cell technology.

This patent application covers an important element of Cynata’s stem cell manufacturing technology.

The technology is among the intellectual property licensed exclusively from the University of Wisconsin–Madison’s Wisconsin Alumni Research Foundation (WARF) to Cynata.

Importantly, the new patent application addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for cellular therapies.

Cynata is developing cellular therapies to treat graft v host disease (GvHD), respiratory disease, cardiovascular disease and a number of other serious conditions.

The phase I clinical trial in GvHD has already commenced in the UK and Australia.

The inventors named on the patent are Dr Maxim Vodyanyk and professor Igor Slukvin, founders, advisors and shareholders of Cynata.

Cynata anticipates that the patent will be granted by October 2017, with an expiration date of 1 February 2028.

Earlier this year the company announced a breakthrough strategic agreement with Fujifilm which included the Japanese company investing A$4 million in Cynata to become its largest shareholder.

The global regenerative medicine market was worth US$18.9 billion in 2016 and is expected to grow to over US$53.7 billion by 2021.

Stem cells are considered as the cornerstone of contemporary regenerative medicine applications.

Quick facts: Cynata Therapeutics Ltd

Price: 0.835 AUD

Market: ASX
Market Cap: $97.8 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cynata Therapeutics Ltd named herein, including the promotion by the Company of Cynata Therapeutics Ltd in any Content on the Site, the Company...


Cynata Therapeutics meets with New York investors following good news from...

Cynata Therapeutics Ltd (ASX:CYP) (OTCMKTS:CYYNF) CEO Ross Macdonald tells Proactive's Christine Corrado the cell therapy company has met the clinical endpoints of a Phase 1 trial of its Cymerus mesenchymal stem cell (MSC) product candidate in people with steroid-resistant acute...

on 09/10/2018

2 min read